Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy

Nezam H. Afdhal, Geoffrey M. Dusheiko, Edoardo G. Giannini, Pei Jer Chen, Kwang Hyub Han, Aftab Mohsin, Maribel Rodriguez-Torres, Sorin Rugina, Igor Bakulin, Eric Lawitz, Mitchell L. Shiffman, Ghias Un Nabi Tayyab, Fred Poordad, Yasser Mostafa Kamel, Andres Brainsky, James Geib, Sandra Y. Vasey, Rita Patwardhan, Fiona M. Campbell, Dickens Theodore

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE)-1 and ENABLE-2, investigated the ability of eltrombopag to increase the number of platelets in patients, thereby allowing them to receive initiation or maintenance therapy with PEG and RBV. Methods Patients with HCV infection and thrombocytopenia (platelet count

Original languageEnglish
JournalGastroenterology
Volume146
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Platelet Count
Antiviral Agents
Fibrosis
Ribavirin
Virus Diseases
Hepacivirus
Thrombocytopenia
Infection
Hepatitis C
Interferons
Liver Diseases
Therapeutics
eltrombopag

Keywords

  • Blood Clot
  • Complication
  • Liver Disease
  • Portal Hypertension

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy. / Afdhal, Nezam H.; Dusheiko, Geoffrey M.; Giannini, Edoardo G.; Chen, Pei Jer; Han, Kwang Hyub; Mohsin, Aftab; Rodriguez-Torres, Maribel; Rugina, Sorin; Bakulin, Igor; Lawitz, Eric; Shiffman, Mitchell L.; Tayyab, Ghias Un Nabi; Poordad, Fred; Kamel, Yasser Mostafa; Brainsky, Andres; Geib, James; Vasey, Sandra Y.; Patwardhan, Rita; Campbell, Fiona M.; Theodore, Dickens.

In: Gastroenterology, Vol. 146, No. 2, 02.2014.

Research output: Contribution to journalArticle

Afdhal, NH, Dusheiko, GM, Giannini, EG, Chen, PJ, Han, KH, Mohsin, A, Rodriguez-Torres, M, Rugina, S, Bakulin, I, Lawitz, E, Shiffman, ML, Tayyab, GUN, Poordad, F, Kamel, YM, Brainsky, A, Geib, J, Vasey, SY, Patwardhan, R, Campbell, FM & Theodore, D 2014, 'Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy', Gastroenterology, vol. 146, no. 2. https://doi.org/10.1053/j.gastro.2013.10.012
Afdhal, Nezam H. ; Dusheiko, Geoffrey M. ; Giannini, Edoardo G. ; Chen, Pei Jer ; Han, Kwang Hyub ; Mohsin, Aftab ; Rodriguez-Torres, Maribel ; Rugina, Sorin ; Bakulin, Igor ; Lawitz, Eric ; Shiffman, Mitchell L. ; Tayyab, Ghias Un Nabi ; Poordad, Fred ; Kamel, Yasser Mostafa ; Brainsky, Andres ; Geib, James ; Vasey, Sandra Y. ; Patwardhan, Rita ; Campbell, Fiona M. ; Theodore, Dickens. / Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy. In: Gastroenterology. 2014 ; Vol. 146, No. 2.
@article{f1b33d85b5a849648cadb08c1fe91172,
title = "Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy",
abstract = "Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE)-1 and ENABLE-2, investigated the ability of eltrombopag to increase the number of platelets in patients, thereby allowing them to receive initiation or maintenance therapy with PEG and RBV. Methods Patients with HCV infection and thrombocytopenia (platelet count",
keywords = "Blood Clot, Complication, Liver Disease, Portal Hypertension",
author = "Afdhal, {Nezam H.} and Dusheiko, {Geoffrey M.} and Giannini, {Edoardo G.} and Chen, {Pei Jer} and Han, {Kwang Hyub} and Aftab Mohsin and Maribel Rodriguez-Torres and Sorin Rugina and Igor Bakulin and Eric Lawitz and Shiffman, {Mitchell L.} and Tayyab, {Ghias Un Nabi} and Fred Poordad and Kamel, {Yasser Mostafa} and Andres Brainsky and James Geib and Vasey, {Sandra Y.} and Rita Patwardhan and Campbell, {Fiona M.} and Dickens Theodore",
year = "2014",
month = "2",
doi = "10.1053/j.gastro.2013.10.012",
language = "English",
volume = "146",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy

AU - Afdhal, Nezam H.

AU - Dusheiko, Geoffrey M.

AU - Giannini, Edoardo G.

AU - Chen, Pei Jer

AU - Han, Kwang Hyub

AU - Mohsin, Aftab

AU - Rodriguez-Torres, Maribel

AU - Rugina, Sorin

AU - Bakulin, Igor

AU - Lawitz, Eric

AU - Shiffman, Mitchell L.

AU - Tayyab, Ghias Un Nabi

AU - Poordad, Fred

AU - Kamel, Yasser Mostafa

AU - Brainsky, Andres

AU - Geib, James

AU - Vasey, Sandra Y.

AU - Patwardhan, Rita

AU - Campbell, Fiona M.

AU - Theodore, Dickens

PY - 2014/2

Y1 - 2014/2

N2 - Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE)-1 and ENABLE-2, investigated the ability of eltrombopag to increase the number of platelets in patients, thereby allowing them to receive initiation or maintenance therapy with PEG and RBV. Methods Patients with HCV infection and thrombocytopenia (platelet count

AB - Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE)-1 and ENABLE-2, investigated the ability of eltrombopag to increase the number of platelets in patients, thereby allowing them to receive initiation or maintenance therapy with PEG and RBV. Methods Patients with HCV infection and thrombocytopenia (platelet count

KW - Blood Clot

KW - Complication

KW - Liver Disease

KW - Portal Hypertension

UR - http://www.scopus.com/inward/record.url?scp=84892769466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892769466&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2013.10.012

DO - 10.1053/j.gastro.2013.10.012

M3 - Article

C2 - 24126097

AN - SCOPUS:84892769466

VL - 146

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -